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Intratumoural immunotherapies for unresectable and
metastatic melanoma: current status and future perspectives
Mark R. Middleton 1, Christoph Hoeller2, Olivier Michielin3, Caroline Robert4, Caroline Caramella5, Katarina Öhrling6 and
Axel Hauschild7
The emergence of human intratumoural immunotherapy (HIT-IT) is a major step forward in the management of unresectable
melanoma. The direct injection of treatments into melanoma lesions can cause cell lysis and induce a local immune response, and
might be associated with a systemic immune response. Directly injecting immunotherapies into tumours achieves a high local
concentration of immunostimulatory agent while minimising systemic exposure and, as such, HIT-IT agents are associated with
lower toxicity than systemic immune checkpoint inhibitors (CPIs), enabling their potential use in combination with other therapies.
Consequently, multiple HIT-IT agents, including oncolytic viruses, pattern-recognition receptor agonists, injected CPIs, cytokines
and immune glycolipids, are under investigation. This review considers the current clinical development status of HIT-IT agents as
monotherapy and in combination with systemic CPIs, and the practical aspects of administering and assessing the response to
these agents. The future of HIT-IT probably lies in its use in combination with systemic CPIs; data from Phase 2 trials indicate a
synergy between HIT-IT and CPIs. Data also suggest that the addition of HIT-IT to a CPI might generate responses in CPI-refractory
tumours, thereby overcoming resistance and addressing a current unmet need in unresectable and metastatic melanoma for
treatment options following progression after CPI treatment.
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BACKGROUND
The standard of care for patients with melanoma whose tumour
burden is limited and disease spread is confined comprises
surgical resection with the intention to cure. In approximately two-
thirds of all cases of primary cutaneous melanoma, disease spread
begins with locoregional metastasis, with about 50% of patients
developing the first metastasis in regional lymph nodes.1 Satellite
or in-transit metastases also frequently occur at readily accessible
cutaneous or subcutaneous locations.1–4 Although resection still,
theoretically, remains an option in such cases, repeated surgery
for locoregional disease might not be the best approach for
patients with disease affecting a large anatomic area, for those in
whom relapse occurs rapidly following repeated surgery, or for
those in whom the morbidity of surgery might outweigh the
benefits.5 In these, and other, patients with unresectable
melanoma, the approval of targeted therapies (such as inhibitors
of BRAF and mitogen-activated protein kinase [MEK]) and immune
checkpoint inhibitors (CPIs; such as anti-programmed death
receptor 1 [PD-1] and anti-cytotoxic T-lymphocyte-associated
protein 4 [CTLA-4] agents) has revolutionised outcomes—with
CPI treatment, around one-third of patients survive at least
5 years.6–10 However, the treatments can result in severe and long-
lasting toxicities, and primary or acquired resistance are com-
mon.8–12 Furthermore, because most Phase 3 trials assessing
targeted therapies or CPIs have predominately enrolled patients
with stage IV disease, limited efficacy data are available for these
agents in the treatment of unresectable stage IIIB–C locoregional
melanoma.13–17
The need for additional treatment options for unresectable
locoregional disease coupled with the accessibility of this type of
metastasis has led to increased interest in immunostimulatory
agents that can be injected directly into the tumour.5 These
intratumoural immunotherapies can cause cell lysis, either directly
or indirectly, and promote the induction of a local immune
response, and might also be associated with the generation of a
systemic immune response.18,19 Importantly, direct injection of a
therapeutic agent into the tumour maximises its concentration at
the disease site, promoting a tumour-specific immune response
while reducing systemic exposure.2 There are anticipated benefits
of combining intratumoural therapy with systemic immunothera-
pies such as CPIs. Not only do they offer different modes of action,
but they also have non-overlapping toxicity profiles.20
Here, we review the latest data on the development of human
intratumoural immunotherapy (HIT-IT), as a single-agent strategy
and in combination with CPIs, for unresectable melanoma,
alongside practical aspects involved in administering and asses-
sing the response to this therapeutic approach. Although some
chemical and local physical and radiation strategies might be
defined as intratumoural therapies (e.g. PV-10 [a 10% solution of
Rose Bengal], electrochemotherapy, cryotherapy, high-intensity
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focused ultrasound, irradiation and liposomal and nano-delivery
systems) these therapeutic options are not immunotherapies and
are thus considered to be outside the scope of this review.21
IDEAL CHARACTERISTICS FOR AN INTRATUMOURAL
IMMUNOTHERAPY
An ideal HIT-IT should elicit a measurable biological effect,
reflective of the mechanism of action, that should lead to an
objective response in the injected tumour.21 The ability to
generate a local complete response and a durable response (i.e.
lasting several months) is important to enable its use as a
monotherapy, since it demonstrates the agent’s effectiveness
when used on its own.21–23 Likewise, local disease control should
translate into clinical benefit (e.g. symptom control, delayed
disease progression, improved survival).22 Ideally, HIT-IT should
stimulate a systemic immune response leading to regression of
uninjected tumours at locoregional and distant metastatic
sites.18,19,21 The initiation of a systemic immune response can
occur through a variety of mechanisms, including the enhanced
release and presentation of tumour antigens, immune cell
trafficking and activation and inhibition of immunosuppressive
pathways.24–27 It is anticipated that HIT-ITs will reach high
concentrations in injected lesions, increasing the local
bioavailability.21,28 Furthermore, by minimising systemic exposure,
HIT-IT should be associated with low toxicity compared with
systemic immunotherapies.22,25,29,30 Moreover, HIT-ITs might be
able to reverse resistance to systemic immunotherapies.31–33
These attributes indicate that HIT-ITs could be used both as
monotherapies and as part of a combination strategy,28 and data
from the past 5 years suggest synergy between intratumoural and
systemic immunotherapies (as described in more detail
below).19,20,34–39
CURRENTLY AVAILABLE HIT-ITS FOR UNRESECTABLE AND
METASTATIC MELANOMA
Talimogene laherparepvec (T-VEC) is the only treatment with
regulatory approval for intratumoural administration in unresect-
able metastatic melanoma, and is recommended in current clinical
practice guidelines.40–44 Interleukin-2 (IL-2) is included in guide-
lines as a systemic treatment for unresectable metastatic
melanoma,43,44 and intratumoural administration has also been
investigated.45–47
T-VEC
T-VEC is a genetically modified oncolytic virus that expresses
granulocyte-macrophage colony-stimulating factor (GM-CSF).48,49
It selectively infects and replicates in tumour cells, which not only
leads to cell lysis but also to the release of GM-CSF. This recruits
dendritic cells, which, in turn, process and present tumour
antigens to cytotoxic T lymphocytes (CTLs), thereby inducing a
systemic tumour-specific immune response.48,49 T-VEC is
approved in Europe for the treatment of adults with stage IIIB,
IIIC and IVM1a unresectable melanoma with no bone, brain, lung
or other visceral disease, and in the USA for the local treatment of
unresectable cutaneous, subcutaneous and nodal lesions in
patients with melanoma recurrent after initial surgery.
The approval of T-VEC was based on data from the OPTiM Phase
3 trial (n= 436), which demonstrated that the durable response
rate (objective response lasting ≥6 months) and overall response
rate were significantly higher following treatment with intrale-
sional T-VEC than with subcutaneous GM-CSF in patients with
unresectable and/or metastatic stage IIIB–IV melanoma (Table 1).22
Efficacy was highest in patients with stage IIIB–IVM1a disease; in
this group, T-VEC led to a survival benefit22 and demonstrated a
tolerable safety profile.22 A systemic immune response is
suggested by observed reductions in the size of uninjected
lesions associated with T-VEC treatment (≥50% reduction in
15–34% of uninjected lesions).18,22 This implication is also
supported by a prospective Phase 2 trial in which T-VEC led to a
significant increase in the number of CD8+ T cells, effector and
memory cytotoxic lymphocytes (CTLs), natural killer cells, and CTLs
expressing PD-1 and CTLA-4 (indicative of immune activation) in
uninjected lesions.50
IL-2
IL-2 is a proinflammatory cytokine that can activate CD8+ T cells,
regulatory T cells, B cells, macrophages and natural killer cells.45,51
Systemically administered IL-2 is approved for the treatment of
metastatic melanoma in the USA,52 but not in Europe.53 To date,
intratumoural treatment with IL-2 has only been studied in single-
arm trials involving a limited number of patients.45–47 Although
responses with intratumoural IL-2 appear to be durable (lasting ≥
6 months), they are largely limited to injected lesions, which
suggests that intratumoural IL-2 does not elicit a strong systemic
effect—at least, not at the doses and regimens that have been
studied.30 Intratumoural IL-2 is generally well tolerated.
NOVEL AGENTS IN DEVELOPMENT FOR UNRESECTABLE AND
METASTATIC MELANOMA
Many agents are being developed for intratumoural use, including
other oncolytic viruses and peptides, pattern-recognition receptor
(PRR) agonists, immune CPIs and cytokines (see Table 1 and below
for further details).21 Figure 1 shows how these agents might
interact with the cancer-immunity cycle, the process by which
cancer cells are effectively killed by an immune response.
Other oncolytic viruses
Given that the only currently approved HIT-IT is an oncolytic virus,
it is not surprising that other oncolytic viruses are undergoing
development for the treatment of unresectable and metastatic
melanoma.54 Coxsackievirus A21 (CVA21) is an enterovirus that
preferentially infects tumour cells, leading to cell lysis, which
appears to provoke a systemic antitumour immune response even
in the absence of the virus encoding an immune component such
as GM-CSF or IL-2.55 In a single-arm Phase 2 trial, CVA21 led to
durable responses lasting 6 months or more.56 No Phase 3 trials
are currently planned for CVA21 monotherapy in melanoma since
the future of these agents is most likely in combination,
particularly with immunotherapies. In this regard, trials are
ongoing with CVA21 in combination with other therapies (see
below). Canerpaturev (formerly HF-10) is a spontaneously
occurring, replication-competent mutant strain of herpes simplex
virus type 1 that causes lysis of infected cells.34,57 Similar to CVA21,
canerpaturev is being assessed in combination therapy; no
monotherapy trials are ongoing. Other oncolytic viruses are in
early clinical development as monotherapy and/or in combination
therapy: RP1 and RP2, engineered strains of the herpes simplex
virus; ONCOS102, an adenovirus engineered to express GM-CSF;
JX-594 (Pexa-Vec), a GM-CSF-expressing poxvirus; and CF33-hNIS,
a chimeric poxvirus encoding a human sodium iodide symporter
(hNIS).58–61
PRR agonists
Another class of HIT-IT in development comprises the PRR
agonists, which include Toll-like receptor (TLR) agonists, stimulator
of interferon genes (STING) agonists and retinoic acid-inducible
gene I (RIG-I)-like receptor agonists.21,62 PRRs are costimulatory
molecules that recognise pathogen-associated molecular patterns
(PAMPs), such as lipopolysaccharide and other bacterial and viral
components, as well as damage-associated molecular patterns
(DAMPs) resulting from cellular stress, apoptosis and necrosis.62
Recognition of PAMPs/DAMPs leads to upregulation of the
transcription of genes involved in inflammatory responses, which
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encode proinflammatory cytokines, type-I interferons, chemo-
kines and, antimicrobial proteins.63 Activation of TLR-9 signalling
in plasmacytoid dendritic cells induces production of interferon-α
and tumour necrosis factor (TNF)-α, which promotes leucocyte
migration and induces synthesis of antimicrobial peptides and
cytokines, and promotes phagocytosis in macrophages.64 Three
TLR-9 agonists (SD-101, IMO-2125 and CMP-001) are in clinical
development in combination therapy (see below).31,32,65,66 RIG-I-
like receptors are cytosolic PRRs that detect viral and endogenous
RNA, triggering binding to the mitochondrial antiviral signalling
protein (MAVS) and resulting in type-I interferon production.62
MK4621 (formerly RGT-100), a synthetic RNA agonist of the RIG-I
pathway, has been shown to have antitumour activity in mouse
models.67 STING is an endoplasmic reticulum transmembrane
protein involved in recognition of cytosolic DNA. In tumours,
STING pathway activation leads to interferon-β production and
T-cell response.62 Cyclic dinucleotides have been found to act as
immune adjuvants by activating STING, in turn stimulating a
proinflammatory immune response;68 Phase 1 trials of two
intratumoural STING agonists, ADU-S100 and MK-1454, are
ongoing.69–71
CPIs
Immune CPIs, such as TNF receptor superfamily agonists (e.g.
CD40) and immunoglobulin superfamily antagonists (e.g. PD-1
and CTLA-4), are also in development as intratumoural agents.21
The activation of CD40 on antigen-presenting cells initiates their
maturation and ability to activate CD8+ T cells. Modulation of this
pathway in melanoma is being evaluated in a Phase 1/2 trial of an
intratumoural CD40 agonist, APX005M.72 The feasibility of utilising
approved anti-PD-1 systemic therapies as intratumoural agents
was demonstrated in a 2018 pilot study; further studies are
needed to determine the efficacy of this approach.73 Similarly,
intratumoural administration of the anti-CTLA-4 antibody ipilimu-
mab plus IL-2 demonstrated the induction of both local and
systemic immune responses in a Phase 1 trial; no dose-limiting
toxicities were reported.27 A Phase 1/2 trial assessing intratu-
moural ipilimumab plus systemic nivolumab, an anti-PD-1 anti-
body, is currently recruiting patients.74
Cytokines
Cytokines (e.g. IL-2 and GM-CSF) were among the first HIT-ITs to
be assessed in melanoma.5 Subsequently, cytokine fusion proteins
Oncolytic viruses and peptides
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Fig. 1 HIT-ITs and the cancer-immunity cycle. The effect of different types of human intratumoural immunotherapy (HIT-IT) agents on
different stages of the cancer-immunity cycle. First, oncogenesis causes tumour-derived antigens (TDAs) to be released (step 1). Dendritic cells
process the TDAs and present them to T cells on major histocompatibility complex class 1 (MHC1) and class 2 (MHC2) molecules (step 2). The
T-cells are primed and activated against the TDAs (step 3), trafficked to the tumour (step 4) and then infiltrated into the tumour bed (step 5).
Here the T cells recognise tumour cells through the interaction of the T-cell receptor with the relevant tumour cell antigen bound to MHC1
(step 6). The T cells then kill the tumour cells (step 7), which releases further TDAs to continue the cycle again, with an expanded response. In
cancer the cycle does not work optimally; HIT-ITs aim to enhance the cycle at several points in the process. Oncolytic viruses and peptides (e.g.
talimogene laherparepvec, Coxsackievirus A21, canerpaturev, RP1, RP2, ONCOS102 and JX-594) act at step 1, causing cell lysis, and in step 2,
by causing release of cytokines that recruit dendritic cells to process TDAs. Pattern-recognition receptor agonists (PRRs, e.g. Toll-like receptor-9
agonists SD-101, IMO-2125 and CMP-001; the RIG-I agonist MK4621 and stimulator of interferon genes (STING) agonists ADU-S100 and MK-
1454) can act at step 2 by provoking upregulation of cytokines in response to recognition of pathogen-associated molecular patterns (PAMPs)
and damage-associated molecular patterns (DAMPs). They can also be involved at steps 4 and 5 by activating TLR-9 signalling to promote
T-cell migration and infiltration into tumours. Checkpoint inhibitors (e.g. the anti-CTLA-4 agent ipilimumab and the CD40 agonist APX005M)
remove inhibitory signals of T-cell activation, enabling T cell priming and activation at step 3, and modulate active immune response in the
tumour bed at step 7. Cytokines (e.g. granulocyte-macrophage colony-stimulating factor, interleukin-2 and daromun) have roles in cancer
antigen presentation at step 2, as well as T cell priming, activation and trafficking at steps 3 and 4. Figure adapted from Immunity volume 39,
Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle, pages 1–10, Copyright (2013), ref. 122 with permission from
Elsevier. TDA tumour-derived antigen.
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and plasmids expressing cytokines have been developed with the
aim of increasing efficacy.75,76 For example, the immunocytokine
fusion protein L19–IL-2 (Darleukin) is a targeted form of IL-2 that
recognises the extra domain B of fibronectin, which is expressed in
cancer-associated blood vessels and extracellular matrix but
absent from almost all healthy tissue.75 In a single-arm Phase 2
trial, L19–IL-2 resulted in local responses, including local complete
responses.75 Daromun, another investigational treatment, com-
bines L19–IL-2 and L19–TNF. In a single-arm Phase 2 trial,
Daromun led to objective responses in both injected and
uninjected lesions. A pivotal trial of Daromun is being conducted
in the neoadjuvant setting.77
Tavokinogene telseplasmid (also called pIL-12) is a synthetic
plasmid encoding the cytokine IL-12, which, when delivered to
melanomas in a highly localised manner, leads to a proinflamma-
tory response, resulting in T-cell recruitment and activation. In a
Phase 2 trial, tavokinogene telseplasmid demonstrated induction
of an antitumour immune response and a high disease control
rate in melanoma.78 Tavokinogene telseplasmid was given orphan
drug status by the US Food and Drug Administration (FDA) in 2017
for the treatment of unresectable metastatic melanoma.76
Other promising HIT-ITs
Several other novel HIT-ITs have shown promising preclinical
antitumour activity and are entering clinical trials. AGI-134 is a
glycolipid that recruits pre-existing endogenous anti-Gal antibodies
to the injected lesion, leading to complement activation and
enhanced tumour antigen processing, whereas IMM60 is a non-
glycolipid that activates invariant natural killer cells, leading to an
antitumour immune response. A Phase 1/2 trial of AGI-134 is
currently recruiting patients, and trials of IMM60 are anticipated.79–81
IFx-Hu2.0 is a plasmid DNA encoding the streptococcal membrane
protein, Emm55, and the first in human Phase 1 study of
intratumoural use in melanoma is in progress.82 Preliminary
laboratory data from the first three patients in the trial suggest
the treatment may be associated with decreases in tumour cells and
formation of an immune response.83 mRNA-2416 is a novel lipid
nanoparticle therapeutic agent encoding the TNF receptor ligand
OX40L. Results so far delivered from an ongoing Phase 1/2 study
indicate that intratumoural mRNA-2416 monotherapy is well
tolerated and elevates PD-L1 levels and proinflammatory activity.84
Going forward
Although many HIT-ITs have been investigated, most data at
present originate from Phase 2 trials only. Such data are difficult to
interpret, because early-stage efficacy might not reflect the results
of Phase 3 trials:85–87 for example, despite promising efficacy in
Phase 2 trials, the plasmid-DNA-based intratumoural immunother-
apy velimogene aliplasmid (a plasmid–lipid complex comprising
the DNA sequences encoding HLA-B7 and β2 microglobulin)
either provided no benefit or reduced survival compared with
standard of care in Phase 3 trials.86 This result highlights the need
for caution when interpreting data from single-arm, non-
randomised trials in small and highly selected patient populations,
as well as emphasising the importance of mechanistic tumour
biology research to enable rational drug and clinical trial design.
COMBINING INTRATUMOURAL AND SYSTEMIC
IMMUNOTHERAPIES
As noted, many intratumoural agents in development are being
assessed in combination with systemic CPIs, reflecting the likely
future clinical application of intratumoural therapy.
HIT-ITs might enhance the response to CPIs...
Although CPIs provide an effective therapeutic approach as
monotherapy in melanoma,6,7 only a subset of patients initially
respond, and a substantial proportion of responders subsequently
develop resistance and relapse.88 Data suggest that therapeutic
responses to immunotherapy can, to some extent, be predicted by
the presence of tumour immune cell infiltration. Three tumour
immune profiles correlate with response to CPIs: inflamed or ‘hot’
tumours exhibiting immune cell infiltration are likely to respond,
whereas ‘cold’ immune-excluded tumours with immune cells
surrounding, but not infiltrating, the tumour, and immune desert
tumours, characterised by a complete lack of immune cells, are less
likely to respond. HIT-ITs that elicit a local immune response have
been shown to promote immune cell infiltration into the tumour in
both injected and uninjected lesions.26,37,50 Consequently, by
altering the tumour microenvironment and converting a non-
responsive ‘cold’ tumour into a responsive ‘hot’ tumour, HIT-IT
might enhance response to systemic immunotherapies.26,37,38
…and CPIs might enhance the response to HIT-ITs
On the other hand, CPIs might also enhance the response to HIT-
IT. Cancer cells can activate immune checkpoint pathways to
downregulate the response to local immunostimulation, thus
limiting the response to intratumoural monotherapy.89,90 Indeed,
a 2018 Phase 2 trial of T-VEC showed that this therapy leads to an
increase in the number of CTLs expressing PD-1 and CTLA-4.50
Blocking PD-1 or CTLA-4 might restore suppressed antitumour
immune responses and enhance the ability of T cells (which have
been primed by intratumoural injection) to recognise and kill
tumour cells.35,91 CPIs might also enhance the systemic effects of
some HIT-ITs.35,37,38,50 Therefore, combination therapy might
result in improved clinical activity beyond what would be
expected with either agent alone. Additionally, owing to the low
toxicity of HIT-IT, combination therapy has the potential to be
tolerated at effective doses.
Combination trials of HIT-ITs with pembrolizumab or ipilimumab
Given the therapeutic promise of combining intratumoural and
systemic immunotherapies, several combination trials have been
conducted or are ongoing (Table 2). Data indicating the
synergistic activity of such combinations are available from the
Phase 1b/3 MASTERKEY-265/KEYNOTE-034 trial of T-VEC plus the
anti-PD-1 agent pembrolizumab versus pembrolizumab alone. In
the combination arm, two injections of T-VEC were given before
pembrolizumab was initiated. Although single-agent T-VEC
increased CD8+ T-cell infiltration into the tumour, in both injected
and uninjected lesions, and increased the numbers of systemic
circulating CD4+ and CD8+ T cells, combination therapy was
associated with greater clinical benefit than that seen previously
with either agent alone, with no additional toxicity.37,92 Longer-
term follow-up (median 36.8 months) of the Phase 1b part of the
trial suggests that this combination induces a high rate of
complete responses (43%), with a 3-year survival rate of ~70%.93
The same combination is currently being evaluated in the large
randomised Phase 3 MASTERKEY-265/KEYNOTE-034 trial.94
Systemic pembrolizumab is being assessed in combination with
various other HIT-ITs, with promising early results. Interim data
from a Phase 1b/2 trial combining the intratumoural TLR-9 agonist
SD-101 with pembrolizumab demonstrated that the combination
is well tolerated and leads to increased tumour immune cell
infiltration, as well as inducing tumour shrinkage, in injected and
uninjected lesions—including those in distant metastases.65,66
Pembrolizumab is also being investigated in a Phase 2 trial with
intratumoural tavokinogene telseplasmid78,95 and in a Phase 1b
trial with the oncolytic virus CVA21. A Phase 2 trial is also planned
to investigate pembrolizumab with CVA21.96 Apart from T-VEC
plus pembrolizumab, none of these combinations is currently
being assessed in Phase 3 trials.
T-VEC has also been assessed in a randomised Phase 1b/2 trial
in combination with ipilimumab versus ipilimumab alone;97 the
results suggest that this combination is tolerable and might have
greater efficacy than either agent alone.39,98,99 Other ipilimumab
Intratumoural immunotherapies for unresectable and metastatic melanoma:. . .
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and intratumoural combinations have shown efficacy in Phase 1b
or 2 trials, including with the oncolytic viruses CVA21 and
canerpaturev.34,100 However, a Phase 2 trial of ipilimumab
combined with intratumoural IL-2 reported no objective
responses.2 Currently there are no ongoing or planned Phase 3
trials of any of these combinations.
Use of HIT-IT following anti-PD-1 therapy
For patients who have previously received an anti-PD-1 agent,
treatment options are limited.88 Data from the past 3 years—
particularly from studies using TLR-9 agonists—indicate that
treatment regimens incorporating a HIT-IT can lead to responses
in patients who have previously received, or who have progressed
following, anti-PD-1 therapy (Table 2).31–33,101 Limited data are
available on the efficacy of HIT-IT as monotherapy in patients who
have previously received an anti-PD-1 therapy.
Several studies are investigating whether combining a HIT-IT
with ipilimumab can provide additional activity. In a Phase 1/2 trial,
addition of the TLR-9 agonist IMO-2125 (tilsotolimod) to ipilimumab
revived the immune response in injected and uninjected anti-PD-1-
resistant tumours.31 A randomised Phase 3 trial assessing IMO-2125
plus ipilimumab in patients who have progressed on previous anti-
PD-1 therapy is ongoing.102 Phase 2 data show that the addition of
canerpaturev to ipilimumab can lead to responses in a minority of
patients previously treated with anti-PD-1 therapy.101
Early phase data indicate that the addition of a HIT-IT to an anti-
PD-1 agent might restore response and fundamentally overcome
resistance to anti-PD-1 therapy. In a Phase 1b trial, the TLR-9
agonist CMP-001 was able to overcome resistance to PD-1
inhibition when combined with pembrolizumab.32 Likewise, in a
Phase 1b/2 trial, addition of the TLR-9 agonist SD-101 to
pembrolizumab restored tumour sensitivity to PD-1 inhibition in
refractory tumours; responses were seen in both injected and
uninjected lesions.33 A Phase 2 trial of T-VEC plus pembrolizumab
is ongoing in patients with advanced melanoma whose disease
progressed following anti-PD-1 therapy.103
For future analyses on the sequence of HIT-ITs, it will be
important to ascertain if the response to these agents differs
among patients who progress following initial response to CPI
treatment compared with those who never respond to CPI
treatment and/or patients who have previously received a CPI and
discontinued for other reasons (e.g. poor tolerability). This will help
to identify the most appropriate HIT-IT to use in different clinical
situations. Another interesting area for future research is the
potential to give HIT-IT to patients who experience progression
despite adjuvant CPI therapy, as many of these patients progress
with accessible locoregional disease only.104
HIT-ITs in combination with targeted therapies
There is also interest in combining HIT-ITs with BRAF and MEK
inhibitors such as dabrafenib and trametinib. This approach aims
to specifically target the BRAF driver mutation, which is present in
around 50% of malignant melanomas.105 The combination of MEK
inhibition and T-VEC has shown increased melanoma tumour cell
death in vitro106 and a Phase 1 trial of dabrafenib, trametinib and
T-VEC is ongoing.107
PRACTICAL IMPLICATIONS OF HIT-IT FOR THE CLINICAL
MANAGEMENT OF UNRESECTABLE AND METASTATIC
MELANOMA
Patient selection
From a practical perspective, HIT-IT can only be administered to
patients with lesions that are visible, palpable or detectable by
ultrasound or other imaging techniques. Key considerations for
the selection of patients for HIT-IT monotherapy are described in
Box 1. The decision to select a patient for HIT-IT should result from
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will change if a HIT-IT is approved in combination with a systemic
CPI. Similarly, a better understanding of the chances of obtaining a
response will help to weigh the risk:benefit consideration in the
case of less accessible lesions (e.g. lung metastases).
Lesion mapping and injection
To ensure accurate drug delivery, response and evaluation, lesion
mapping using clinical evaluation (i.e. palpation and imaging)
should be conducted to identify and measure lesions for injection.
Lesions that will not be injected should also be mapped to enable
the assessment of systemic responses. Ultrasound provides an
accessible option for the mapping of most lesions (including
subcutaneous and nodal), as well as allowing the measurement of
3D tumour volume, and can be more accurate than palpation for
the determination of lesion size. Computed tomography (CT),
positron emission tomography (PET-CT) and, in rare cases,
magnetic resonance imaging can also be considered for mapping
deep lesions or those located in the extremities. Before initiating
HIT-IT, it is important to record the tumour load throughout the
patient, the tumour volume available for injection and the total
volume of agent injected before response evaluation. Both
injected and uninjected lesions (including visceral lesions) should
be measured before treatment and compared with previous
measurements: a lesion tracking sheet and high-resolution
photographs could facilitate lesion tracking.
It is beyond the scope of this review to detail handling and
administration for HIT-IT; these topics have been covered
extensively by Marabelle et al.,21 Gutzmer et al.108 and Harrington
et al.109. Briefly, most cutaneous, subcutaneous and superficial
lymph node lesions can be injected under ultrasound guidance.21
Multiple injections can be administered to a single lesion, and
multiple lesions can be injected at the same visit.21 The choice of
whether to use the same needle for all lesions or individual
needles for each lesion might depend on the type of HIT-IT used
and the risk of drug exposure to the patient or healthcare
professional.21,41 Intratumoural injections should be performed by
a trained healthcare professional (e.g. a nurse, physician,
radiologist, interventional radiologist or surgeon).21
Electroporation is sometimes employed for delivery of tavoki-
nogene telseplasmid and other plasmids. After injection of the
plasmid into the lesion, application of electroporation pulses
locally permeabilise and transduce the cells.110 The precision of
the technique is an advantage. Only cells that are exposed to both
the plasmid and the electrical field will undergo transfection,
enabling local, targeted delivery.110
Safety and tolerability of intratumoural injections
As mentioned, most reported adverse events associated with HIT-
IT have generally been mild and might not require active
treatment. Injection-site reactions are frequent, but they tend to
resolve within 24–48 h and can be helped with ice and pain relief.
Local anaesthetic can be given ~30min before the procedure.
Careful wound care is important to help to avoid skin infections. In
the event of cellulitis, oral or intravenous antibiotics should be
administered as required and blood samples taken for culture.111
Although HIT-IT is generally associated with low toxicity, adverse
events such as fatigue, chills and pyrexia have been reported in
clinical trials and it is important to manage the patient’s
expectations of tolerability to ensure that they remain on
treatment.18,22,112
Assessment of response
Current trials of HIT-ITs have used a range of response criteria.
Thorough and consistent assessments of response will be required
in future clinical trials to properly evaluate the plethora of HIT-ITs
in development. The Response Evaluation Criteria in Solid Tumors
(RECIST v1.1) were designed to measure responses to cytotoxic
agents, and might not be suitable for evaluating HIT-ITs: according
to RECIST v1.1, new lesions define progressive disease, but the
appearance of new lesions can precede prolonged disease
stabilisation in response to immune checkpoint blockade.113
Indeed, pseudoprogression, in which a tumour appears to grow
as a result of a treatment effect rather than true disease
progression, has been reported to occur in patients receiving
HIT-IT;18 in such cases, discontinuing treatment at the point of
apparent initial disease progression might not be appropriate. The
immune-related response criteria (irRC) and immune-related (ir)
RECIST partially ameliorate these issues by requiring confirmation
of progressive disease by consecutive imaging assessment at least
4 weeks from the date of the first documentation and by
incorporating the measurement of new lesions into the sum of
lesions.114–116 irRECIST further attempts to harmonise data
collection and to clarify response measurement that allows for
pseudoprogression. New lesions are assessed separately. Impor-
tantly, the progressive disease thresholds for irRECIST are aligned
with RECIST v1.1, allowing comparisons to be made between trials
and historical data.
European Society for Medical Oncology (ESMO) recommenda-
tions on the development of HIT-ITs propose that, for clinical trials,
RECIST v1.1 is used for the overall assessment of tumour response,
iRECIST is used for assessing responses of injected and uninjected
tumours, and the duration of response for both injected and
uninjected lesions should be reported.21 We are in agreement
with the ESMO recommendations that injected lesions are
evaluated separately from uninjected lesions, to characterise
systemic effects in clinical trials.21 As a result, the evaluation of
HIT-IT in clinical trials is more complex than for conventional
therapies, due to the need to differentiate lesions (e.g. ‘target
injected’, ‘target non-injected’, ‘non-target’, ‘new target’ and ‘new
non-target’). Furthermore, visceral lesions must be considered in
the response criteria; responses to HIT-IT have been reported in
uninjected visceral lesions, and advances in imaging guidance
techniques now allow visceral lesions to be directly injected.31
Such complexity in response assessment requires specially trained
radiologists.
These assessment criteria are currently likely to be too
complicated and not relevant for real-world practice, in which
treatment decisions are based on patient-level responses, and
harmonisation on how to evaluate tumour response to HIT-IT is
still awaited. As HIT-IT becomes more widely used, the link
between formal response evaluation, clinical benefit and decision-
making in practice will evolve further.
CONCLUSIONS
The efficacy and tolerability of HIT-IT for the treatment of
melanoma provide proof-of-concept for this modality. Early data
Box 1. Patient selection for HIT-IT monotherapy
Several key considerations exist for HIT-IT monotherapy patient selection:
When surgery is no longer an option owing to a number of reasons22,108,123,124
● tumour location, leading to unreasonable morbidity (e.g. cutaneous head
and neck melanoma)
● risk of surgical complications
● presence of numerous in-transit lesions
● disease recurrence despite multiple surgical interventions
As an alternative to systemic therapy in patients
● for whom systemic therapies are contraindicated or poorly tolerated
● with slowly progressing disease or locoregional progression but stable
visceral metastases who wish to avoid systemic therapy
● who wish to preserve systemic therapies for later treatment lines in the
event of disease progression
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indicate the existence of a synergy between HIT-IT and CPIs, and it
is likely that future clinical use will focus on the combined use of
these agents; indeed strategies that combine treatments that have
different modes of action without overlapping toxicities are likely to
feature in future research. Furthermore, there is a high unmet need
in unresectable and metastatic melanoma for treatment options
following progression after PD-1 inhibition, and data indicate that
adding HIT-IT to systemic agents can lead to responses in anti-PD-
1-refractory tumours, thereby overcoming resistance.
The development of HIT-IT has focused on unresectable disease;
however, there is now interest in the efficacy of this approach in
the neoadjuvant setting, and early data suggest that neoadjuvant
HIT-IT could prevent recurrence following surgery in patients with
resectable melanoma.117,118 Additionally, although it has been
widely assessed in melanoma, HIT-IT could be considered for use
in any tumour that is injectable (including under image
guidance).21 Consequently, a plethora of HIT-ITs are in early-
stage clinical development for the treatment of a range of solid
tumour types and lymphoma.
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